Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

Leadership Strategy

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Deals Business Strategies

Finance Watch: Biopharma VC Explosion Extends To Tools, Services

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Financing Innovation

SERB Pays $800m For Boston Scientific Specialty Pharma Business

The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.

Deals M & A

Digital Scrip Awards Celebrate Biopharma After An Exceptional Year

The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.

Companies Research & Development

Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma

The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.

Respiratory Deals

AZ Sells EU Rights To Former Jewel In The Crown, Crestor

The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.

Deals Cardiovascular

Biogen And Sage On Plans To Build A Brain Franchise Together

The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.

Deals Neurology

Biogen Bets Big To Bag Sage Depression And Tremor Drugs

Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.

Deals Neurology
See All
UsernamePublicRestriction

Register